Diabetic Macular Edema (DME) Clinical Trial
— BLUE SKYOfficial title:
OBservationaL stUdy to Evaluate Fluid reSolution and Effectiveness in Patients Receiving Beovu (Brolucizumab) Under KeY Treatment Schemes in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
Verified date | May 2024 |
Source | Novartis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study is a prospective, non-interventional, multicenter, open-label study in nAMD and DME patients being treated with brolucizumab according to the EU SmPC. An observational study design, without a strict, mandated visit schedule or mandated treatment regimen was chosen as the most appropriate to collect available data in a real life setting. For that reason, this NIS does not impose a therapy protocol, diagnostic/therapeutic procedure or a visit schedule. The diagnostic or monitoring procedures are only those ordinarily applied to the therapeutic strategy and to routine clinical care and will take place as per investigator's discretion. This includes e.g. visit frequency, injection frequency and types of assessments performed - only data from routine medical practice will be collected as part of the study.
Status | Active, not recruiting |
Enrollment | 573 |
Est. completion date | December 20, 2025 |
Est. primary completion date | December 20, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: The unit of analysis is patient-eye, i.e. all criteria should be applied to the study eye, unless otherwise specified. Patients will be included in the study if they fulfil the following requisites: 1. Diagnosis of nAMD or visual impairment due to DME 2. Male and Female nAMD and DME patients with =18 years of age at index 3. Decision to treat with brolucizumab at baseline visit 4. Signed written informed consent 5. Patients for whom a therapy with brolucizumab is medically indicated 6. Intraretinal and/or subretinal fluid affecting the central subfield of the study eye at Screening Exclusion Criteria: 1. Patients that have any contraindication or are not eligible for treatment with brolucizumab as according to the SmPC 2. Patients treated for RVO or CNV other than nAMD 3. Receipt of any anti-VEGF treatment other than brolucizumab in the study eye at index date 4. Central subfield of the study eye affected by fibrosis or geographic atrophy or total area of fibrosis >50% of the total lesion (nAMD) 5. Any active intraocular or periocular infection or active intraocular inflammation in either eye at index date 6. Patients who have been on anti-VEGF treatment for longer than 3 years (before index date) 7. Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the 24 months study participation 8. Patients participating in parallel in an interventional clinical trial 9. Patients participating in parallel in any other NIS generating primary data for an anti-VEGF drug 10. Laser photocoagulation (focal/grid or panretinal) in the study eye during the 3-month period prior to baseline 11. Prior use of intraocular or periocular corticosteroids in the study eye provided at least 4 months prior to baseline 12. Pregnancy and breast-feeding |
Country | Name | City | State |
---|---|---|---|
Germany | Novartis Investigative Site | Aschersleben | |
Germany | Novartis Investigative Site | Bayreuth | |
Germany | Novartis Investigative Site | Berlin | |
Germany | Novartis Investigative Site | Berlin | |
Germany | Novartis Investigative Site | Bonn | |
Germany | Novartis Investigative Site | Breisach am Rhein | |
Germany | Novartis Investigative Site | Chemnitz | |
Germany | Novartis Investigative Site | Dresden | |
Germany | Novartis Investigative Site | Dresden | |
Germany | Novartis Investigative Site | Dresden | |
Germany | Novartis Investigative Site | Esslingen | |
Germany | Novartis Investigative Site | Frankfurt | |
Germany | Novartis Investigative Site | Glauchau | |
Germany | Novartis Investigative Site | Gottingen | |
Germany | Novartis Investigative Site | Halle | |
Germany | Novartis Investigative Site | Homburg | |
Germany | Novartis Investigative Site | Hösbach | |
Germany | Novartis Investigative Site | Jena | |
Germany | Novartis Investigative Site | Kiel | |
Germany | Novartis Investigative Site | Koeln | |
Germany | Novartis Investigative Site | Leipzig | |
Germany | Novartis Investigative Site | Leipzig | |
Germany | Novartis Investigative Site | Magdeburg | |
Germany | Novartis Investigative Site | Marienberg | |
Germany | Novartis Investigative Site | Muenchen | |
Germany | Novartis Investigative Site | Muenster | |
Germany | Novartis Investigative Site | Neubrandenburg | |
Germany | Novartis Investigative Site | Neuburg | |
Germany | Novartis Investigative Site | Osnabrück | |
Germany | Novartis Investigative Site | Rostock | |
Germany | Novartis Investigative Site | Saarbruecken | |
Germany | Novartis Investigative Site | Schneeberg | Sachsen |
Germany | Novartis Investigative Site | Schoenebeck | |
Germany | Novartis Investigative Site | Stralsund | |
Germany | Novartis Investigative Site | Sulzbach | |
Germany | Novartis Investigative Site | Torgau | |
Germany | Novartis Investigative Site | Trier | RP |
Germany | Novartis Investigative Site | Waren | |
Germany | Novartis Investigative Site | Wuerzburg | |
Germany | Novartis Investigative Site | Wuerzburg | Bayern |
Lead Sponsor | Collaborator |
---|---|
Novartis Pharmaceuticals |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of patients' eyes that are absent of subretinal fluid (SRF) and intra-retinal fluid (IRF) | This outcome measure is part of the BLUE SKY AMD module. This primary study objective will be addressed considering treatment naïve and pre-treated patient eyes, analyzed as two independent groups (naïve and switch). | Month 12 | |
Primary | Mean change in visual actuity (VA) under clinic specific routine treatment schemes | This outcome measure is part of the BIRL module. This primary study objective will be addressed considering treatment naïve patient eyes.
Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye. |
Baseline, month 12 | |
Primary | Morphological CNV-Changes under clinic specific routine treatment schemes | This outcome measure is part of the BIRL module. This primary study objective will be addressed considering treatment naïve patient eyes.
Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye. |
Baseline, month 12 | |
Primary | Percent of patients maintained on q12w dosing after loading through Week 52 | This outcome measure is part of the BLUE SKY DME module. This primary study objective will be addressed considering treatment naïve patient eyes included in the study. | After loading, month 12 | |
Primary | Change in interval length from last interval before switch (baseline) to last interval at end of follow-up (12 months) | This outcome measure is part of the BLUE SKY DME module. This primary study objective will be addressed considering pre-treated patient eyes. Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eyes. | Baseline, month 12 | |
Secondary | Characterize nAMD patients who initiated treatment with brolucizumab with the respect to baseline characteristics | nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan | Baseline | |
Secondary | Evaluate anatomical parameters during treatment with brolucizumab | nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan. | Up to month 24 | |
Secondary | Evaluate VA change from baseline during treatment with brolucizumab | nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan. | Baseline, month 24 | |
Secondary | Estimate number of anti-VEGF injections, visits and injection intervals | nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan | Up to month 24 | |
Secondary | Estimate percentage of switchers during first 6 months and characterize switchers | nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan | Baseline, month 6 | |
Secondary | Estimate discontinuation rate and time to discontinuation | nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan | Month 1-12 and 13-24 | |
Secondary | Assess retreatment criteria | nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan | Up to month 24 | |
Secondary | Estimate the number of OCT | nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan | Month 1-12 and 13-24 | |
Secondary | Assess the safety of brolucizumab | nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan | Up to month 24 | |
Secondary | Evaluate anatomical effectiveness | naive nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan | Up to month 24 | |
Secondary | Evaluate treatment intervals | naive nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan | Up to month 24 | |
Secondary | Describe implementation of treatment schemes into clinical practice | naive nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan | Up to month 24 | |
Secondary | Evaluate morphological changes under brolucizumab treatment using multimodal imaging | naive nAMD patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan | Up to month 24 | |
Secondary | Percentage of patient's eyes with absence of IRF and/or SRF at month 12 (naive and switch) | DME patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan | Month 12 | |
Secondary | Evaluate anatomical parameters during treatment with brolucizumab | DME patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan | Month 1-12 and 13-24 | |
Secondary | Characterize VA change from baseline during treatment with brolucizumab | DME patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan | Month 1-12 and 13-24 | |
Secondary | Estimate discontinuation rate during first year of brolucizumab treatment | DME patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan | Baseline, month 12 | |
Secondary | Estimate time to discontinuation (persistence) | DME patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan | Up to month 24 | |
Secondary | Estimate the treatment burden | DME patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan | Month 1-12 and 13-24 | |
Secondary | Estimate the number of OCT and the number of visits with/without OCT | DME patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan. | Month 1-12 and 13-24 | |
Secondary | Assess safety of brolucizumab | DME patients. Detailed Outcome Measure will be defined in the Statistical Analysis Plan. | Up to month 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01702441 -
Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema
|
Phase 1/Phase 2 | |
Completed |
NCT02424019 -
Phase 4 IOP Signals Associated With ILUVIEN®
|
Phase 4 | |
Completed |
NCT02633852 -
Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema
|
Phase 4 | |
Completed |
NCT04857996 -
Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)
|
Phase 2 | |
Recruiting |
NCT05919693 -
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
|
Phase 1/Phase 2 | |
Completed |
NCT04739306 -
Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema
|
Phase 3 | |
Recruiting |
NCT06116916 -
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
|
Phase 2 | |
Completed |
NCT02050828 -
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
|
Phase 2 | |
Recruiting |
NCT03859245 -
Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention
|
N/A | |
Completed |
NCT02585401 -
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada
|
N/A | |
Terminated |
NCT02080091 -
Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies
|
N/A | |
Terminated |
NCT04697758 -
Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema
|
Phase 1/Phase 2 | |
Terminated |
NCT00936520 -
SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy
|
Phase 1 | |
Not yet recruiting |
NCT06398080 -
An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
|
||
Active, not recruiting |
NCT05989126 -
Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
|
Phase 3 |